Papers by Victoria Ibecheole
BMJ (Clinical Research Edition), Feb 12, 2000
Medecine Et Hygiene, 1999
Le diabete gestationnel est une complication frequente de la grossesse, associee a une augmentati... more Le diabete gestationnel est une complication frequente de la grossesse, associee a une augmentation de la morbidite maternelle et perinatale, ainsi qu'a un risque de developpement ulterieur du diabete de type 2. Cette affection est depistee par le test de O'Sullivan, suivi d'une hyperglycemie provoquee orale. Les femmes presentant un diabete gestationnel sont prises en charge par une equipe multidisciplinaire. Le traitement comprend le regime et, eventaellement, une insulinetherapie, La prevention des complications obstetricales inclus la surveillance du bien-etre fœtal, la detection de la macrosomie foetale et des signes de preeclampsie. Pour certaines femmes, une provocation de l'accouchement ou une cesarienne elective sont necessaires. Les differents aspects du diagnostic et de la prise en charge du diabete gestationnel a la maternite de Geneve sont discutes.
Revue medicale de la Suisse romande, 1998
We have been confronted in our centre with numerous cases of Bell's palsy in the pregnant pat... more We have been confronted in our centre with numerous cases of Bell's palsy in the pregnant patient. The aetiology of this lesion is discussed. A typical case is exposed.
BMJ (Clinical research ed.), Jan 12, 2000
Revue médicale de la Suisse romande, 1998
We have been confronted in our centre with numerous cases of Bell's palsy in the pregnant pat... more We have been confronted in our centre with numerous cases of Bell's palsy in the pregnant patient. The aetiology of this lesion is discussed. A typical case is exposed.
Journal of Biological Chemistry, 2008
heparan sulfate proteoglycans bind and activate antithrombin by virtue of a specific 3-O-sulfated... more heparan sulfate proteoglycans bind and activate antithrombin by virtue of a specific 3-O-sulfated pentasaccharide. They not only occur in the vascular wall, but also in extravascular tissues, such as the ovary, where their functions remain unknown. The rupture of the ovarian follicle at ovulation is one of the most striking examples of tissue remodelling in adult mammals. It involves tightly controlled inflammation, proteolysis and fibrin deposition. We hypothesized that ovarian heparan sulfates may modulate these processes through interactions with effector proteins. Our previous work has shown that anticoagulant heparan sulfates are synthesized by rodent ovarian granulosa cells and we now have set out to characterize heparan sulfates from human follicular fluid. Here, we report the first anticoagulant heparan sulfate purified from a natural human extravascular source. Heparan sulfate chains were fractionated according to their affinity for antithrombin and their structure was analyzed by 1 H-NMR and MS/MS. We find that human follicular fluid is a rich source of anticoagulant heparan sulfate, comprising 50.4% of total heparan sulfate. These antithrombin-binding chains contain more than 6% 3-O-sulfated glucosamine residues, convey an anticoagulant activity of 2.5 IU/ml to human follicular fluid, and have an anti-Factor Xa specific activity of 167 IU/mg. The HS chains that do not bind antithrombin surprisingly exhibit an extremely high content in 3-O-sulfated glucosamine residues, which suggest that they may exhibit biological activities through interactions with other proteins.
Human Reproduction, 2001
BACKGROUND: Cervicitis is believed to alter cytological interpretation and could compromise a com... more BACKGROUND: Cervicitis is believed to alter cytological interpretation and could compromise a combined screening for Chlamydia trachomatis (CT) cervicitis and squamous intra-epithelial lesions (SIL). Liquid-based cytological methods have been shown to limit obscuring factors and permit the detection of infectious agents by DNA amplification techniques. The aim of this study was to evaluate a combined screening for SIL and CT cervicitis with a single liquid-based cervical sample. METHODS: Two cervical samples were obtained from each of 590 women considered at high risk for CT. The modified Ligase chain reaction (LCR) procedure for CT detection using specimens collected in the AutoCyte's preservative fluid was compared with the conventional Abbott LCx method using cervical swabs. We have also compared the percentage of inflammatory specimens and adequacy of cellular material in the populations of CT⍣ and CT-women. RESULTS: The results show total agreement for 588 of 590 cervical samples using the two LCR protocols (Kappa ⍧ 0.96; 95% confidence interval: 0.91-1.00). The quality of cervical cytology was not compromised by CT cervicitis. CONCLUSIONS: We demonstrated the feasibility of combined screening for CT and SIL with a single liquid-based cervical sample.
Fertility and Sterility, 2012
Background: A randomized controlled trial (RCT) comparing highly purified human Choriogonadotroph... more Background: A randomized controlled trial (RCT) comparing highly purified human Choriogonadotrophin (HP-hCG) and recombinant hCG (r-hCG) both administered subcutaneously for triggering ovulation in controlled ovarian stimulation (COS) for Assisted Reproductive Technology (ART). Methods: Multi-centre (n = 4), prospective, controlled, randomized, non-inferiority, parallel group, investigator blind design, including 147 patients. The trial was registered with www.clinicaltrials.gov, using the identifier: NCT00335569. The primary endpoint is the number of oocytes retrieved, while the secondary endpoints include embryo implantation, pregnancy and delivery rates as well as safety parameters. Results: The number of retrieved oocytes was not inferior when HP-hCG was used as compared to r-hCG: the mean number was 13.3 (6.8) in HP-hCG and 12.5 (5.8) in the r-hCG group (p = 0.49) with a 95% CI (−1.34, 2.77). Regarding the secondary outcomes, there were also no differences in fertilization rate at 57.3% (467/815) vs. 61.3% (482/787) (p = 0.11), the number of embryos available for transfer and cryopreservation (2PN stage) and implantation, pregnancy and delivery rates. Furthermore, there were no differences in the number and type of adverse events reported. HP-hCG was therefore not inferior to r-hCG. Conclusions: HP-hCG and r-hCG are equally efficient and safe for triggering ovulation in ART and, both being administered subcutaneously, equally practical and well tolerated by patients.
Fertility and Sterility, 2009
Objective: To compare the prevalence of intermediate and premutation FMR1 alleles in women with o... more Objective: To compare the prevalence of intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency (oPOI) and in controls. Design: Observational study. Setting: Patient(s): The study group consisted of 27 infertile women with oPOI referred by infertility specialists for FMR1 testing in 2005-6 because of unexplained poor response to controlled ovarian hyperstimulation or altered hormonal profiles. The control group consisted of 32 women undergoing genetic testing for conditions unrelated to mental retardation or ovarian function. The DNA samples were anonymized. Intervention(s): In the study group, data were collected concerning reproductive/family history, hormonal markers, possible fertility treatment outcomes, and results of karyotype and FMR1 testing. In the control group, FMR1 gene testing was done. The only clinical data available in controls were sex and indication for genetic testing. Main Outcome Measure(s): Distribution of FMR1 alleles. Result(s): Six (22%) of 27 women with oPOI had FMR1 alleles of >40 repeats (intermediate to premutation range), compared with one (3%) of 32 controls. Conclusion(s): These results suggest that women with oPOI might be at risk of carrying alleles in the intermediate and premutation range. (Fertil Steril Ò 2009;92:464-70.
Fertility and Sterility, 2008
Objective: To investigate whether oral or vaginal administration of contraceptive hormones might ... more Objective: To investigate whether oral or vaginal administration of contraceptive hormones might affect anti-m€ ullerian hormone (AMH) levels. Design: Prospective trial with women recruited by advertisement. Women who wished contraception were randomized between oral or vaginal estroprogestative contraception, and those who did not choose contraception were included in the control group. Setting: Fertility clinic of a tertiary university hospital. Patient(s): Twenty-four young, healthy volunteer women with regular cycles who had received no hormonal contraception for at least 3 months before the study. Intervention(s): Oral or vaginal estroprogestative contraception from day 5 to 25 of a menstrual cycle versus no contraception. Main Outcome Measure(s): Intercycle and intracycle variations of serum AMH levels in normally ovulating volunteers and following the initiation of oral or vaginal estroprogestative contraception. Result(s): Fluctuations of AMH levels observed during the menstrual cycle remained within cycle-to-cycle variability in cycling controls and in women receiving oral or vaginal contraception. Conclusion(s): Our findings confirm that AMH levels remain steady during the menstrual cycle and indicate that they are unaffected by exogenous sex steroids used for contraception whether administered orally or vaginally. (Fertil Steril Ò 2008;90:395-400.
Fertility and Sterility, 2010
Fertility and Sterility, 2008
Objective: To discuss, on the basis of the experience of two clinical cases and extensive literat... more Objective: To discuss, on the basis of the experience of two clinical cases and extensive literature review, the significance of extremely low levels of anti-M€ ullerian hormone (AMH), also known as M€ ullerian-inhibiting substance, in infertile women. Design: Case report. Setting: University-based infertility clinic at a medical center in Switzerland. Patient(s): Two women, 29 and 41 years of age and with a 2-and 4-year history of secondary infertility, respectively. Intervention(s): Clinical, radiological, and biological investigation of infertility, including repeated measurements of the serum AMH with serial ELISA assays. Main Outcome Measure(s): Levels of AMH and development of ongoing pregnancy. Result(s): Both women had a spontaneous ongoing pregnancy despite undetectable AMH levels.
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2002
Clinical Obstetrics and Gynecology, 2006
Acta Obstetricia et Gynecologica Scandinavica, 2000
Annals of the New York Academy of Sciences, 2004
In the long history of controlled ovarian hyperstimulation (COH), two steps stand out as being th... more In the long history of controlled ovarian hyperstimulation (COH), two steps stand out as being the most important ones for providing the high efficacy of current treatments: the introduction of GnRH agonists for the prevention of premature ovulation and the widespread use of pretreatment with oral contraceptives before COH for in vitro fertilization. Interestingly, the benefits of both measures resulted largely from pure serendipity, as the discovery of these advantages was mostly fortuitous and/or unintended. Today, we believe that two areas of research have the highest potential for further improving the efficacy of COH: (1) switching the follicle-stimulating hormone stimulus to that of luteinizing hormone (or small amounts of hCG) in the last stages of COH; and (2) using the benefit of the new third-generation aromatase inhibitors that have recently become available. The effects of the latter products are to enhance the endogenous production of gonadotropins (mostly FSH). This article reviews the background data and rationale that justifies each of these two new developments and summarizes data currently available.
Uploads
Papers by Victoria Ibecheole